354 related articles for article (PubMed ID: 31799246)
1. Theranostic Nanomedicine for Malignant Gliomas.
d'Angelo M; Castelli V; Benedetti E; Antonosante A; Catanesi M; Dominguez-Benot R; Pitari G; Ippoliti R; Cimini A
Front Bioeng Biotechnol; 2019; 7():325. PubMed ID: 31799246
[TBL] [Abstract][Full Text] [Related]
2. Towards tailored management of malignant brain tumors with nanotheranostics.
Aparicio-Blanco J; Torres-Suárez AI
Acta Biomater; 2018 Jun; 73():52-63. PubMed ID: 29678675
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: Theranostic Nanomedicine for Malignant Gliomas.
d'Angelo M; Castelli V; Benedetti E; Antonosante A; Catanesi M; Dominguez-Benot R; Pitari G; Ippoliti R; Cimini A
Front Bioeng Biotechnol; 2019; 7():468. PubMed ID: 32083065
[TBL] [Abstract][Full Text] [Related]
4. Gold Nanoparticles in Glioma Theranostics.
Norouzi M
Pharmacol Res; 2020 Jun; 156():104753. PubMed ID: 32209363
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and novel therapeutic approaches in malignant glioma.
Desjardins A; Rich JN; Quinn JA; Vredenburgh J; Gururangan S; Sathornsumetee S; Reardon DA; Friedman AH; Bigner DD; Friedman HS
Front Biosci; 2005 Sep; 10():2645-68. PubMed ID: 15970525
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine.
Sharma HS; Muresanu DF; Castellani RJ; Nozari A; Lafuente JV; Tian ZR; Sahib S; Bryukhovetskiy I; Bryukhovetskiy A; Buzoianu AD; Patnaik R; Wiklund L; Sharma A
Int Rev Neurobiol; 2020; 151():1-66. PubMed ID: 32448602
[TBL] [Abstract][Full Text] [Related]
7. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
8. Endovascular therapies for malignant gliomas: Challenges and the future.
Su YS; Ali R; Feroze AH; Li G; Lawton MT; Choudhri O
J Clin Neurosci; 2016 Apr; 26():26-32. PubMed ID: 26857294
[TBL] [Abstract][Full Text] [Related]
9. Targeted brain delivery nanoparticles for malignant gliomas.
Pinto MP; Arce M; Yameen B; Vilos C
Nanomedicine (Lond); 2017 Jan; 12(1):59-72. PubMed ID: 27876436
[TBL] [Abstract][Full Text] [Related]
10. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
11. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
13. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Germano IM; Emdad L; Qadeer ZA; Binello E; Uzzaman M
Cancer Gene Ther; 2010 Sep; 17(9):664-74. PubMed ID: 20523363
[TBL] [Abstract][Full Text] [Related]
14. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for malignant gliomas: a local affair?
Rainov NG; Söling A; Heidecke V
Neurosurg Focus; 2006 Apr; 20(4):E9. PubMed ID: 16709040
[TBL] [Abstract][Full Text] [Related]
16. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
17. Malignant gliomas can be converted to non‑proliferating glial cells by treatment with a combination of small molecules.
Oh J; Kim Y; Baek D; Ha Y
Oncol Rep; 2019 Jan; 41(1):361-368. PubMed ID: 30365111
[TBL] [Abstract][Full Text] [Related]
18. Benign Glioma.
Wu PB; Filley AC; Miller ML; Bruce JN
Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934
[TBL] [Abstract][Full Text] [Related]
19. Rediscovering Potential Molecular Targets for Glioma Therapy Through the Analysis of the Cell of Origin, Microenvironment and Metabolism.
Guo X; Wang T; Huang G; Li R; Da Costa C; Li H; Lv S; Li N
Curr Cancer Drug Targets; 2021; 21(7):558-574. PubMed ID: 33949933
[TBL] [Abstract][Full Text] [Related]
20. Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy.
Sharma R; Mody N; Agrawal U; Vyas SP
Mini Rev Med Chem; 2017; 17(18):1746-1757. PubMed ID: 26891932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
